SunTrust Robinson Humphrey Downgrades Summit Therapeutics plc (SMMT) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
June 27, 2018 7:00 AM EDTEzutromid Development to be DiscontinuedSummit to Focus on Advancing its Pipeline of New Mechanism AntibioticsConference Call Scheduled for 8:00am EDT / 1:00pm BST
OXFORD, United Kingdom and CAMBRIDGE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT) today announces PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy (DMD). PhaseOut DMD was a multi-centre, open-label Phase 2 clinical trial of the... More
